- CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.
- -
-
Paragraph 000505; 000506
(2018/01/17)
-
- MCT4 INHIBITORS FOR TREATING DISEASE
-
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are als
- -
-
Paragraph 0243
(2016/12/26)
-
- N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG
-
The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
- -
-
Page/Page column 62
(2013/06/06)
-
- N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG
-
The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
- -
-
Page/Page column 57
(2013/06/06)
-
- ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES
-
This disclosure relates to compounds, compositions and methods for the treatment of various disorders. In particular, the disclosure relates to thiazolotriazole and thiazoloimidazole compounds which agonize the activity of the protein TGR5. Formula (I)
- -
-
Page/Page column 42
(2013/04/13)
-
- Process for the production of a dihydroxybenzene and dicarbinol from diisopropylbenzene
-
Improved methods for the simultaneous production of dihydroxybenzene and dicarbinol from diisopropylbenzene are provided. These methods provide for continuous and simultaneous production of diisopropylbenzene dihydroperoxide (DHP) and diisopropylbenzene hydroxyhydroperoxide (HHP) using Karr Column extractors operated in series. A very high purity DHP-containing solution, the precursor to the dihydroxybenzene, can be produced according to the reported methods. A safe and efficient method for producing dicarbinol from HHP is also disclosed.
- -
-
-
- Biocatalysed synthesis of the enantiomers of the floral odorant Florhydral
-
The two enantiomers of the floral odorant Florhydral were prepared by enzymatic methods, and their olfactory properties were evaluated. (+)-Florhydral was found to be much more powerful than the (-)-enantiomer.
- Abate, Agnese,Brenna, Elisabetta,Dei Negri, Claudia,Fuganti, Claudio,Serra, Stefano
-
p. 899 - 904
(2007/10/03)
-
- Synthesis of 2-indanones via [4 + 1] annulation reactions of (trialkylsilyl)arylketenes
-
(Matrix presented) (Trialkylsilyl)arylketenes combine with (trimethylsilyl)diazomethane in a new [4 + 1] annulation process leading to 2-indanone derivatives. The (trialkylsilyl)arylketene annulation substrates are available via the photochemical Wolff rearrangement of α-silyl-α-diazo ketones, which are themselves prepared by silylation of the corresponding diazo ketones. The mechanism of the annulation reaction is proposed to involve the formation of a 2,3-bis(silyl)cyclopropanone, which is in equilibrium with an oxyallylic cation. Electrocyclic closure of this intermediate forms the new cyclopentenone ring.
- Dalton, Audra M.,Zhang, Yongjun,Davie, Christopher P.,Danheiser, Rick L.
-
p. 2465 - 2468
(2007/10/03)
-